Prostate Cancer
Research


Volume 7 Number 10
October 2019


Home > Disciplines > Publications > Prostate Cancer Research > Volume 7, Year 2019 > Number 10, October



CONTENTS


CASE REPORTS
DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
INTEGRATIVE MEDICINE
PROGNOSIS
TREATMENT



CASE REPORTS


Mahdy A, Patil R, Parajuli S.
Biochemical Recurrence in Prostate Cancer and Temporal Association to Bone Metastasis.
Am J Case Rep. 2019 Oct 16;20:1521-1525. doi: 10.12659/AJCR.918569.
Source . Similar articles



DIAGNOSIS


Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA.
Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Sep 6. doi: 10.1007/s00259-019-04506-1. [Epub ahead of print]
Source . Similar articles




Atilla MK, Avci B, Irkilata L, Aydin M, Bitkin A, Keleş M, Yücel I, Ulubay M.
Does transrectal ultrasonography-guided biopsy of the prostate lead to possible further metastasis via circulating tumor cells?
Turk J Med Sci. 2019 Oct 27. doi: 10.3906/sag-1904-58. [Epub ahead of print]
Source . Similar articles




Baghdanian AA, Kim YJ, Baghdanian AH, Nguyen HN, Shinohara K, Westphalen AC.
Differences in negative predictive value of prostate MRI based in men with suspected or known cancer.
Radiol Bras. 2019 Sep-Oct;52(5):281-286. doi: 10.1590/0100-3984.2018.0126.
Source . Similar articles




Cook GJR.
Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Oct 17. doi: 10.1007/s00259-019-04540-z. [Epub ahead of print]
Source . Similar articles
Comment on: Amorim BJ, et al., Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Sep 6. doi: 10.1007/s00259-019-04506-1. [Epub ahead of print] Source . Similar articles




Dai J, Zhang X, Zhao J, Sun G, Chen J, Liu J, Tao R, Zeng H, Shen P.
The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy.
Medicine (Baltimore). 2019 Oct;98(43):e17633. doi: 10.1097/MD.0000000000017633.
Source . Similar articles




De Luca S, Fiori C, Bollito E, Garrou D, Aimar R, Cattaneo G, De Cillis S, Manfredi M, Tota D, Massa F, Passera R, Porpiglia F.
Risk of Gleason Score 3 + 4 = 7 prostate cancer upgrading at radical prostatectomy is significantly reduced by target biopsy compared to standard biopsy technique.
Minerva Urol Nefrol. 2019 Oct 10. doi: 10.23736/S0393-2249.19.03367-8. [Epub ahead of print] -
Source . Similar articles




Huang GL, Kang CH, Lee WC, Chiang PH.
Comparisons of cancer detection rate and complications between transrectal and transperineal prostate biopsy approaches - a single center preliminary study.
BMC Urol. 2019 Oct 28;19(1):101. doi: 10.1186/s12894-019-0539-4.
Source . Similar articles




Joosse SA, Beyer B, Gasch C, Nastały P, Kuske A, Isbarn H, Horst LJ, Hille C, Gorges TM, Cayrefourcq L, Alix-Panabières C, Tennstedt P, Riethdorf S, Schlomm T, Pantel K.
Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer.
Clin Chem. 2019 Oct 10. doi: 10.1373/clinchem.2019.310912. [Epub ahead of print]
Source . Similar articles




Leeman JE, Chen MH, Huland H, Graefen M, D'Amico AV, Tilki D.
Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer.
Clin Genitourin Cancer. 2019 Aug 5. doi: 10.1016/j.clgc.2019.07.018. [Epub ahead of print]
Source . Similar articles




Pasqualetti F, Panichi M, Sollini M, Sainato A, Galli L, Morganti R, Chiacchio S, Marciano A, Zanca R, Mannelli L, Coraggio G, Sbrana A, Cocuzza P, Montrone S, Baldaccini D, Gonnelli A, Molinari A, Cantarella M, Mazzotti V, Ricci S, Paiar F, Erba PA.
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Oct 16. doi: 10.1007/s00259-019-04482-6. [Epub ahead of print]
Source . Similar articles




Rührup J, Preisser F, Theißen L, Wenzel M, Roos FC, Becker A, Kluth LA, Bodelle B, Köllermann J, Chun FKH, Mandel P.
MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?
Front Surg. 2019 Sep 18;6:55. doi: 10.3389/fsurg.2019.00055.
Source . Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION


Cardwell CR, O'Sullivan JM, Jain S, Harbinson MT, Cook MB, Hicks BM, Mc Menamin ÚC.
The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies.
Epidemiology. 2019 Oct 21. doi: 10.1097/EDE.0000000000001132. [Epub ahead of print] -
Source . Similar articles




Wang Y, Gieschen H, Greenberger M, Yu X, Tian G, VanderWalde N, Stockstill T, Farmer M, Rinker L, Izaguirre EW, Somer B, Ballo MT.
Survival After Robotic-Assisted Prostatectomy for Localized Prostate Cancer: An Epidemiologic Study.
Ann Surg. 2019 Oct 28. doi: 10.1097/SLA.0000000000003637. [Epub ahead of print] -
Source . Similar articles



INTEGRATIVE MEDICINE


Abel S, Renz P, Hasan S, White R, Dawodu D, Wegner RE, Fuhrer R.
Alternative Medicine and Oncology: Erroneous Biochemical Failure Following Herbal Supplementation in Early-Stage Prostate Cancer.
J Am Osteopath Assoc. 2019 Nov 1;119(11):763-767. doi: 10.7556/jaoa.2019.126. -
Source . Similar articles




Wang K, Gerke TA, Chen X, Prosperi M.
Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study.
Cancer Med. 2019 Oct 8. doi: 10.1002/cam4.2500. [Epub ahead of print]
Source . Similar articles



PROGNOSIS


Dahut WL, Couvillon A, Pinto PA, Turkbey B, Karzai F.
Natural history and imaging in men with high genetic risk for developing prostate cancer.
Can J Urol. 2019 Oct;26(5S2):7-8.
Source . Similar articles




Froehner M, Koch R, Farahzadi S, Heberling U, Borkowetz A, Twelker L, Baretton GB, Wirth MP, Thomas C.
Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy.
Urol Int. 2019;103(4):427-432. doi: 10.1159/000500961. Epub 2019 Oct 29.
Source . Similar articles




Herlemann A.
Pretreatment Risk Stratification Tools for Prostate Cancer-Moving from Good to Better, Toward the Best.
Eur Urol. 2019 Nov 3. doi: 10.1016/j.eururo.2019.10.016. [Epub ahead of print]
Source . Similar articles
Comment on: Zelic R, et al, Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. Eur Urol. 2019 Oct 9. doi: 10.1016/j.eururo.2019.09.027. [Epub ahead of print] Source . Similar articles




Hou G, Zheng Y, Wei D, Li X, Wang F, Tian J, Zhang G, Yan F, Zhu Z, Meng P, Yuan J, Gao M, Li Z, Zhang B, Xing Z, Yuan J.
Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer.
Medicine (Baltimore). 2019 Sep;98(39):e17197. doi: 10.1097/MD.0000000000017197.
Source . Similar articles




Jambor I, Falagario U, Ratnani P, Perez IM, Demir K, Merisaari H, Sobotka S, Haines GK, Martini A, Beksac AT, Lewis S, Pahikkala T, Wiklund P, Nair S, Tewari A.
Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score.
J Magn Reson Imaging. 2019 Sep 30. doi: 10.1002/jmri.26928. [Epub ahead of print]
Source . Similar articles




Knipper S, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI.
Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis.
Urol Oncol. 2019 Oct 22. doi: 10.1016/j.urolonc.2019.09.015. [Epub ahead of print]
Source . Similar articles




Kvåle R, Myklebust TÅ, Fosså SD, Aas K, Ekanger C, Helle SI, Honoré A, Møller B.
Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients.
Prostate. 2019 Dec;79(16):1852-1860. doi: 10.1002/pros.23911. Epub 2019 Sep 30.
Source . Similar articles




Leufgens F, Berneking V, Vögeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M.
Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer.
Acta Oncol. 2019 Oct 9:1-7. doi: 10.1080/0284186X.2019.1675905. [Epub ahead of print]
Source . Similar articles




Li J, Guo Y, Qiu S, He M, Jin K, Zheng X, Tu X, Liao X, Yang L, Wei Q.
Significance of tertiary Gleason pattern 5 in patients with Gleason score 7 after radical prostatectomy: a retrospective cohort study.
Onco Targets Ther. 2019 Sep 2;12:7157-7164. doi: 10.2147/OTT.S218001.
Source . Similar articles




Lin TT, Chen YH, Wu YP, Chen SZ, Li XD, Lin YZ, Chen SH, Zheng QS, Wei Y, Xu N, Xue XY.
Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients.
J Cancer. 2019 Sep 7;10(22):5608-5613. doi: 10.7150/jca.30731.
Source . Similar articles




Soga N, Ogura Y, Wakita T, Kageyama T, Furusawa J.
The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer.
Curr Urol. 2019 Sep;13(1):25-30. doi: 10.1159/000499298. Epub 2019 Sep 10.
Source . Similar articles




Tomisaki I, Ikuta H, Higashijima K, Onishi R, Minato A, Fujimoto N.
Oncological Outcome After Radical Prostatectomy without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution.
Cancer Invest. 2019 Oct 10:1-7. doi: 10.1080/07357907.2019.1675076. [Epub ahead of print]
Source . Similar articles




Wong KF, Lambert PC, Mozumder SI, Broggio J, Rutherford MJ.
Conditional crude probabilities of death for English cancer patients.
Br J Cancer. 2019 Nov;121(10):883-889. doi: 10.1038/s41416-019-0597-0. Epub 2019 Oct 11.
Source . Similar articles




Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A.
Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
Eur Urol. 2019 Oct 9. doi: 10.1016/j.eururo.2019.09.027. [Epub ahead of print]
Source . Similar articles



TREATMENT


Baumgarten L, Borchert A, Sood A, Dalela D, Arora S, Keeley J, Rogers C, Peabody J, Menon M, Abdollah F.
Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort.
Urol Oncol. 2019 Oct 22. doi: 10.1016/j.urolonc.2019.09.012. [Epub ahead of print]
Source . Similar articles




Boeri L, Sharma V, Nehra A, Kwon E, Karnes RJ.
The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience.
Urol Oncol. 2019 Oct 22. doi: 10.1016/j.urolonc.2019.09.016. [Epub ahead of print]
Source . Similar articles




Bravi CA, Tin A, Vertosick E, Mazzone E, Bandini M, Dell'Oglio P, Stabile A, Gandaglia G, Fossati N, Sjoberg D, Touijer K, Cozzarini C, Briganti A, Montorsi F, Eastham J, Vickers A.
Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy.
Urol Oncol. 2019 Oct 22. doi: 10.1016/j.urolonc.2019.09.018. [Epub ahead of print]
Source . Similar articles




Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S.
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Lancet Oncol. 2019 Oct 16. doi: 10.1016/S1470-2045(19)30486-3. [Epub ahead of print]
Source . Similar articles




D'Amico AV.
Post-operative salvage androgen deprivation and radiotherapy for prostate cancer.
Lancet Oncol. 2019 Oct 16. doi: 10.1016/S1470-2045(19)30488-7. [Epub ahead of print]
Source . Similar articles
Comment on: Carrie C, et al.,Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019 Oct 16. doi: 10.1016/S1470-2045(19)30486-3. [Epub ahead of print] Source . Similar articles




Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
Source . Similar articles




de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med. 2019 Sep 30. doi: 10.1056/NEJMoa1911206. [Epub ahead of print]
Source . Similar articles




Enokida H, Yamada Y, Tatarano S, Yoshino H, Yonemori M, Sakaguchi T, Nishimura H, Eura R, Nakagawa M.
Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
Jpn J Clin Oncol. 2019 Oct 28. pii: hyz138. doi: 10.1093/jjco/hyz138. [Epub ahead of print]
Source . Similar articles




Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabrò F, Tema G, Leonardo C, Flammia RS, Tuderti G, Anceschi U, Brassetti A, Giacinti S, Guaglianone S, Ghahhari J, Schips L, Tubaro A, Gallucci M, Simone G.
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.
World J Urol. 2019 Oct 12. doi: 10.1007/s00345-019-02974-6. [Epub ahead of print]
Source . Similar articles




Panje C, Zilli T, Pra AD, Arnold W, Brouwer K, Garcia Schüler HI, Gomez S, Herrera F, Khanfir K, Papachristofilou A, Pesce G, Reuter C, Vees H, Zwahlen D, Putora PM.
Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.
Radiat Oncol. 2019 Oct 16;14(1):177. doi: 10.1186/s13014-019-1383-0.
Source . Similar articles




Serretta V, Valerio MR, Costa R, Tripoli V, Murabito A, Princiotta A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari M, Sanfilippo C; members of the GSTU Foundation.
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Urol Oncol. 2019 Dec;37(12):964-969. doi: 10.1016/j.urolonc.2019.08.009. Epub 2019 Oct 7.
Source . Similar articles




Takahara K, Sumitomo M, Fukaya K, Jyoudai T, Nishino M, Hikichi M, Zennami K, Nukaya T, Ichino M, Fukami N, Sasaki H, Kusaka M, Shiroki R.
Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases.
Oncol Lett. 2019 Oct;18(4):3896-3902. doi: 10.3892/ol.2019.10692. Epub 2019 Jul 31.
Source . Similar articles




Taşçı Aİ, Şimşek A, Şam E, Şeker KG, Atar FA, Şahin S.
Perineoscopic radical prostatectomy: A novel surgical technique for the treatment of prostate cancer.
Turk J Urol. 2019 Oct 25. doi: 10.5152/tud.2019.19052. [Epub ahead of print]
Source . Similar articles




Vazquez-Martul D, Barbagelata-Lopez A, Lopez-Fernandez A, Chantada-Abal V.
Laparoscopic radical prostatectomy with no anastomosis.
Urol Case Rep. 2019 Sep 5;27:101005. doi: 10.1016/j.eucr.2019.101005.
Source . Similar articles



bottom